In vivo antibacterial activity of MRX-I, a new oxazolidinone

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 2418-2421

  Li, Cong Ran ^a   Zhai, Qian Qian ^a   Wang, Xiu Kun ^a   Hu, Xin Xin ^a   Li, Guo Qing ^a   Zhang, Wei Xin ^a   Pang, Jing ^a   Lu, Xi ^a   Yuan, Hong ^b,c   Gordeev, Mikhail Fedorovich ^b,c   Chen, Le Tian ^d   Yang, Xin Yi ^a   You, Xue Fu ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b MicuRx Pharmaceuticals Inc   (United States)

^c MicuRx Pharmaceuticals Inc   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; LINEZOLID; MRX I; OXAZOLIDINONE DERIVATIVE; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENTEROCOCCUS; EXPERIMENTAL INFECTION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS; STREPTOCOCCUS;

ANIMALS; ANTI-BACTERIAL AGENTS; FEMALE; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; OXAZOLIDINONES; PENICILLINS; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 84896972571     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01526-13     Document Type: Article

References (7)

1. CLSI. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically - 7th edition. Approved standard M07-A9, Clinical and Laboratory Standards Institute Wayne, PA.
2. NCCLS. 1999. Methods for determining bactericidal activity of antimicrobial agents. Approved guideline M26-A. National Committee for Clinical Laboratory Standards Wayne, PA.
3. O'Reilly T, Andes DA, Østergaard C, Frimodt-Møller N. 2005. Evaluation of antimicrobials in experimental animal infections, p 654-718. In Lorian V (ed), Antibiotics in laboratory medicine. Lippincott Williams & Wilkins, Philadelphia, PA.
4. Litchfield JT, Jr, Wilcoxon F. 1949. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96:99-113.
5. Louie A, Liu W, Kulawy R, Drusano GL. 2011. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob. Agents Chemother. 55:3453-3460. http://dx.doi.org/10.1128/AAC.01565-10.
6. Reyes N, Aggen JB, Kostrub CF. 2011. In vivo efficacy of the novel aminoglycoside ACHN-490 in murine infection models. Antimicrob. Agents Chemother. 55:1728-1733. http://dx.doi.org/10.1128/AAC.00862-10.
7. Li CR, Li Y, Li GQ, Yang XY, Zhang WX, Lou RH, Liu JF, Yuan M, Huang P, Cen S, Yu LY, Zhao LX, Jiang JD, You XF. 2010. In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone. J. Antimicrob. Chemother. 65:2411-2415. http://dx.doi.org/10.1093/jac/dkq341.